Fat and medical uses thereof

Microfragmented adipose tissue effectively treats sepsis by reducing inflammation and improving survival through immune modulation, addressing the limitations of current treatments and their long-term complications.

JP2024164094AInactive Publication Date: 2024-11-26LIPOGEMS INT SRL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024135852
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-05-13
Filing Date
2024-08-16
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for sepsis are limited and often ineffective, leading to high mortality rates and long-term health complications such as muscle weakness, cognitive impairment, and organ failure, with a need for new therapies to address the systemic inflammatory response and cytokine storm associated with the condition.

Method used

Administration of microfragmented adipose tissue, particularly through the intraperitoneal route, which reduces inflammation and reverses functional impairments by modulating immune responses and promoting tissue repair.

Benefits of technology

Microfragmented adipose tissue significantly reduces pro-inflammatory cytokines, enhances anti-inflammatory cytokines, improves survival rates, and mitigates long-term effects of sepsis, including muscle weakness and cognitive impairment, by restoring organ function and reducing immune cell infiltration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164094000001_ABST
    Figure 2024164094000001_ABST
Patent Text Reader

Abstract

To provide a composition for use in the treatment of a systemic disease, preferably associated with or caused by sepsis.SOLUTION: The present invention provides micro-fragmented fat or a composition comprising micro-fragmented fat. Moreover, the micro-fragmented fat or the composition comprising the micro- fragmented fat is used for treating a systemic, inflammatory, immune, or chronic disease, the disease being intended as a consequence of septic disease. Preferably, the micro-fragmented fat is useful for treating both acute (early) and late stages of sepsis.SELECTED DRAWING: Figure 4
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for treating a systemic disease, preferably one associated with or caused by sepsis. Micro-fragmentation for use in the treatment of various systemic diseases mented) relates to a composition comprising adipose tissue or microfragmented adipose tissue. Additionally, microfragmented adipose tissue or compositions comprising microfragmented adipose tissue may be used to treat systemic diseases, It is used to treat an inflammatory, immune or chronic disease, said disease being sepsis. It is intended to be the result of a disease. Preferably, the microfragmented adipose tissue treats both the acute (early) and late phases of sepsis. It is useful to [Background technology]

[0002] Sepsis, or systemic inflammatory response syndrome, is a physiological and pathological condition induced by infection. It is defined as a syndrome of multiple myeloma, cerebrovascular disease, and biochemical abnormalities that can lead to vascular leakage, tissue damage, and multiple organ dysfunction. This leads to a systemic, uncontrolled inflammatory response that leads to inflammation. Furthermore, there are currently few treatments available. Because antimicrobial therapy is ineffective, sepsis is fatal in 30% to 40% of cases. Sepsis is reported to be the cause of death for over 200,000 people annually in the United States. It is being done. Thus, sepsis significantly increases the overall cost of health care. Although there have been recent improvements in the management of patients with sepsis, sepsis-related morbidity remains elevated. For example, in half of cases, the condition of surviving patients is complicated by acquired neuromyopathy. Complicated by this, patients experience muscle weakness and wasting, energy problems, and protein metabolism problems. The solution may result in long-term disability. The harmful effects associated with sepsis are due, in part, to uncontrolled inflammation that damages tissues and organs. In addition, widespread activation of inflammatory pathways leads to multiple organ failure, This progresses to collapse of the circulatory system and ultimately death. Summary of the Invention [Problem to be solved by the invention]

[0003] Considering all the above-mentioned points, these types of systemic diseases, especially those related to sepsis, There remains a strong felt need to develop new / alternative therapies to treat . [Means for solving the problem]

[0004] The present invention provides a method for the treatment of adipose tissue comprising administering microfragmented adipose tissue, preferably via the intraperitoneal route. , resolving the need reported above. Indeed, the Applicant has surprisingly found that, for example, sepsis treated with microfragmented adipose tissue Patients with sepsis are at the mercy of most of the adverse effects associated with or caused by sepsis. More interestingly, the use / administration of microfragmented adipose tissue showed a reduction in reversed functional impairments specific to both the acute and late phases of sepsis. The use / administration of microfragmented adipose tissue may, inter alia, reduce organ failure and / or injury, muscle weakness or The present invention is effective in relieving the long-term effects associated with sepsis, such as chronic obstructive pulmonary disease (COPD) and cognitive impairment.

[0005] Indeed, the applicants have demonstrated improved survival and morbidity in mice treated with microfragmented adipose tissue. They observed a sustained reduction in body temperature and sepsis scores in treated mice. normalization of physiological parameters, reduction of pro-inflammatory cytokine levels, and anti-inflammatory cytokines In addition, treated mice showed increased levels of IL-1 in the liver and lungs. Finally, administration of microfragmented adipose tissue reduced the severity of nitric oxide-related complications associated with the later stages of sepsis. Allows for the reversal of neuromyopathy and muscle weakness / wasting. [Brief description of the drawings]

[0006] [Figure 1] Sepsis scores in CLP mice injected with Lipogems (microfragmented adipose tissue) or saline (A–B), and sepsis scores and survival rates in LPS-treated mice injected with or without Lipogems (microfragmented adipose tissue) (C–D) are shown. [Diagram 2] Survival rate (A) and body temperature (B) of CLP mice injected with saline or Lipogems (microfragmented adipose tissue). [Diagram 3] Plasma levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), creatine kinase (CK) and lactate dehydrogenase (LDH) in CLP mice injected with saline or Lipogems (microfragmented adipose tissue) (A); white blood cell counts (B–C) are shown. [Figure 4] 1 shows pro-inflammatory cytokine levels in CLP mice injected with or without Lipogems (microfragmented adipose tissue). [Diagram 5] The numbers of F4 / 80+, B220+ and CD3+ cells in the liver and kidney of CLP mice injected with or without Lipogems (microfragmented adipose tissue) are shown. [Figure 6] Inflammatory scores (A), survival rates (B), white blood cell counts (C), and pro-inflammatory cytokine levels (D) of CLP mice injected with Lipogems, Lipogems+indomethacin, Lipogems+SC-560, and Lipogems+LS-398 (Lipogems = microfragmented adipose tissue) are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0007] The first aspect of the present invention relates to a method for treating a systemic disease or condition, preferably sepsis, or in the treatment of a systemic disease or condition caused by sepsis. The present invention relates to microfragmented adipose tissue or a composition comprising microfragmented adipose tissue for the treatment of adipose tissue infection. In other words, according to the present invention, microfragmented adipose tissue is a therapeutic agent for treating a systemic disease or condition. Preferably, the systemic disease is associated with or caused by sepsis. The adverse health effects associated with a systemic condition, preferably sepsis-related or Ameliorate (restore and / or save) the long-term effects caused by diabetes It is useful for (expenses incurred). Thus, the first aspect of the present invention relates to a method for treating a systemic condition or disease, preferably sepsis. Methods for treating diseases / conditions associated with or caused by sepsis The method further comprises administering to an individual in need thereof an effective amount of microfragmented adipose tissue or microfragmented adipose tissue. The method includes at least one step of administering a composition comprising fragmented adipose tissue. The disease or condition is preferably a systemic disease / condition, an inflammatory disease / condition, an immune disease / condition. or a chronic disease / condition, said disease / condition being caused by a septic disease / condition. It is intended to be rubbed.

[0008] According to a preferred embodiment, the disease or condition is a disorder characterized by a prostaglandin synthesis and / or is associated with a non-COX target. Thus, the condition or disease is mediated by a non-COX target. . In other words, the disease or condition does not involve the COX, preferably the COX-2 pathway. Indeed, inhibitors of these enzymes do not impair the therapeutic effect of the present invention.

[0009] In this context, a systemic condition or disease is defined as a condition that affects several organs and tissues or is defined as a condition or disease that also affects the entire body. In this context, sepsis is also referred to as systemic inflammatory response syndrome. In this context, sepsis or systemic inflammatory response syndrome is a condition that results in vascular leakage, tissue damage and / or or infection resulting in a systemic, uncontrolled inflammatory response leading to multiple organ failure. Especially in the later stages of sepsis, these effects are associated with neuromyopathy, muscle weakness in septic patients. , which can lead to energy failure, protein breakdown, muscle wasting, and even death. In this regard, the adverse health effects associated with sepsis are preferably related to neuromyocytes. Pathopathy, energy failure, protein breakdown, muscle wasting, acute kidney and liver damage, multiorgan damage This is chosen from organ failure and possibly death.

[0010] Preferably, the acute damaging effects are changes in body temperature, cytokine storms (significant and rapid and PCT (procalcitonin) elevation. Late adverse effects (or long-term effects of sepsis) preferably include organ failure and and / or injury, acute lung injury, shock, kidney failure, muscle loss and / or decline, cognitive impairment Disturbances in function (insomnia, nightmares, vivid hallucinations and panic attacks, extreme fatigue, poor concentration, mental decline in function, loss of self-esteem and self-confidence, and multiple organ dysfunction syndrome (MODS). It is selected. Preferably, the microfragmented adipose tissue is non-enzymatic microfragmented adipose tissue. Therefore, the fat used / administered in the present invention is microfragmented without any enzymatic treatment. It is being done.

[0011] According to a further preferred embodiment of the present invention, microfragmented adipose tissue, preferably lipoaspirate, The adipose tissue is preferably removed by using a Lipogems® device. The process is fully disclosed in patent application WO 2011 / 145075. The process is followed. Preferably, the isolated fat is introduced into a Lipogems® device and lightly absorbed. and in the presence of a solution, preferably saline, to form small tissue clusters. is progressively reduced (fragmented) to Preferably, the microfragmented fat has a size of 50 to 5000 μm, preferably 100 to 3000 μm. m, more preferably 200 to 2500 μm, more preferably 300 to 1500 μm, It preferably contains fat clusters having a size in the range of 400 to 900 μm. More preferably, these fat clusters are derived from mesenchymal stem cells (MSCs) and / or peripheral blood. endothelial cells, preferably pericyte-associated MSCs and / or adipose stem cells and / or endothelial cells and / or fibroblasts and / or adipocytes. These cells maintain their niche, which indicates that the cells maintain their native / intact stromal vascular niche. Advantageously, therefore, these cells are provided with nutrients and / or Furthermore, these are supported by the fact that the cells are protected from the invasive environment during transplantation. and protected from any physical and chemical external aggressions (e.g. mechanical, oxygen, etc.) .

[0012] According to a preferred embodiment of the present invention, non-microfragmented tissue, i.e. The microfragmentation process disclosed in WO 2011 / 145075 Microfragmented adipose tissue, preferably lipoaspirated tissue, is more effective than untreated adipose tissue, preferably lipoaspirated tissue. Alternatively, microfragmented lipoaspirate tissue may have a higher microvascular content and preferably is CD31+ The content of CD31+ cells is higher, and more preferably, the content of CD31+ cells is 5-10 times higher.

[0013] According to a further preferred embodiment of the present invention, the non-microfragmented tissue, i.e. The microfragmentation process disclosed in patent application WO 2011 / 145075 Microfragmented adipose tissue compared to unprocessed adipose tissue, preferably aspirated adipose tissue. Preferably, the microfragmented lipoaspirate tissue has a greater vascular content and / or pericyte content. , i.e., a higher number of NG2-positive cells.

[0014] Therefore, the microfragmented adipose tissue of the present invention, preferably the microfragmented adipose tissue, is preferably Wow, - clusters of tissue with a size ranging from 50 to 5000 μm; and / or - mesenchymal stem cells (MSC) and / or pericytes, preferably pericyte-associated MS C and / or adipose stem cells and / or endothelial cells and / or fibroblasts and and / or adipocytes; and / or - preferably free of blood residues and pro-inflammatory oily substances Includes.

[0015] These cells, preferably adipose mesenchymal stem cells, are characterized by the expression of CD44, CD73, CD90, and CD 105, at least one selected from CD146 and CD166, preferably all Express markers, preferably OCT4, SOX2, NANOG, b-tubulin I II NESTIN, NEUROD1, MUSASHI1, PAX6, and SOX3 At least one marker selected from the following, and more preferably all markers, are expressed. More preferably, the cells express nestin, b-tubulin III, GFAP, and Co-express O4. The controlled fat fragmentation can be achieved by using one or more fragmentation / disaggregation ( This is made possible by the use of disaggregation measures. Preferably, the means is a metal means, more preferably a metal bead, said bead comprising: Preferably, 0.1 to 30 mm, preferably 1 to 20 mm, more preferably 5 to 10 mm, more preferably having a size in the range of 7.5 to 8.5 mm. The controlled shaking of the device allows for fragmentation / dissociation throughout the adipose tissue. This allows for gentle movement of the fat media, thus resulting in gentle fat fragmentation / separation. This will be possible. Preferably, the fragmentation / separation is carried out in a flowing saline buffer, more preferably in oil and The procedure is carried out in a continuous flow of saline buffer, which allows for the removal of blood debris and

[0016] The fat fragmentation / separation step preferably takes 15-20 minutes. Microfragmented adipose tissue is produced by using gentle, enzyme-free, sterile, rapid intraoperative manipulation. It can be obtained. The adipose tissue of the present invention is preferably derived from a human. According to a preferred embodiment, the adipose tissue is human adipose tissue, more preferably from an individual. Human adipose tissue, more preferably isolated / aspirated fat tissue, from the lower abdominal and / or flank region. It is a weave. However, the adipose tissue may be isolated from any useful body area. Preferably, the adipose tissue, preferably the microfragmented adipose tissue, is autologous or xenogeneic. . According to a preferred embodiment of the present invention, the individual suffering from sepsis is a human being. According to a further preferred embodiment of the present invention, the sepsis is hospital-acquired or The disease is associated with a bacterial, fungal or viral infection.

[0017] Preferably, the septic condition / disease according to the present invention involves misregulation of pro-inflammatory molecules, said molecules being The child is preferably IL-1a, IL-1b, IL-2, IL-5, IL-6, IL-1 2, IL-17, GM-CSF, IFN-g, MIP-1a, MIP-1b, RANTE S, procalcitonin (PCT) molecule and creatine kinase (CK) and TNF- a, but is not limited to these. Preferably, the septic condition / disease according to the present invention involves misregulation of anti-inflammatory molecules, said molecules is preferably selected from IL-4, IL-10, IL-13 and G-CSF , but not limited to these. Indeed, after administration of microfragmented fat in septic patients, anti-inflammatory molecules were upregulated, Pro-inflammatory molecules are downregulated. Thus, the microfragmented fat preferably contains IL-1a, IL-1b, IL-2, IL-5 , IL-6, IL-12, IL-17, GM-CSF, IFN-g, MIP-1a, MI P-1b, RANTES, or other pro-inflammatory molecules. and / or preferably IL-4, IL-10, IL-13 and G-CS The compound may be used / administered to increase an anti-inflammatory molecule selected from F.

[0018] According to a preferred embodiment of the present invention, a systemic disease or condition, preferably sepsis or The present invention relates to a microorganism for use in the treatment of conditions associated with (caused by) sepsis. Fragmented fat is distributed throughout the body, including the abdominal cavity, intramuscular, alveolar, nasal, pulmonary, subarachnoid space, and lamina cribrosa (lamina cribrosa ( via the nasal passage (preferably via the nasal passage), or via the lymphatic system. The most preferred route of administration is the intraperitoneal route. The composition comprising the fragmented adipose tissue or microfragmented adipose tissue may be administered by itself or in combination with other or in combination with further molecules, preferably anti-inflammatory and / or antibacterial agents. .

[0019] According to a preferred embodiment, the administration comprises the further treatment: - Surgery at the site of infection; and / or - Hemodynamic re-equilibration, preferably by injection of electrolytes; and / or - Cardiotropes and / or vasoactive administration of a molecule (e.g., a catecholamine) that is an active agent; and / or - corticotherapy, preferably in low doses; and / or Or - breathing, preferably assisted by ventilation; and / or - Hemodialysis and / or insulin therapy, and / or - Blood transfusion relating to or following these. Preferably, use / administration is as soon as possible after sepsis symptoms appear according to current clinical practice. This is done within the first 6 hours (known in the medical community as the golden hour) or Administration occurs several days and / or weeks after sepsis symptoms appear. EXAMPLES

[0020] Mice and housing conditions All protocols comply with French and European legislation on animal welfare and with public It was inspected by the supervisory authority, the Institut Pasteur, for compliance with the recommendations of the Public Health Service. The mice used were male C57Bl / 6RJRJ mice aged 6 to 10 weeks. If the inflammatory score at a given time point was greater than 21, or if there was evidence of respiratory rate or quality Mice were euthanized when the points increased beyond 322. The total number of animals used per experimental point was 5 for non-CLP controls and 7 for CLP. The number of mice was 1 for the control group and 7 for the CLP+Lipogems® group. For LPS challenge, n=4 animals were used as control, n=4 animals as LPS n=8 animals in the control group and n=8 animals in the LPS+Lipogems® group. A pathogen culture was used in a temperature- and humidity-controlled laboratory with a 12:12 light / dark cycle. Mice were housed in a body-free facility. Food and drink were available ad libitum. ,The ARRIVE guidelines for good practice experimental research were followed.

[0021] Cecal ligation and puncture (CLP) and lipopolysaccharide (LPS) injection Two mouse models of sepsis were used in this study: 1. Cecal ligation and puncture (CLP) model This was done using CL as a model of inflammation in 6- to 10-week-old male C57Bl / 6RJRJ mice. The CLP model consisted of peritonitis induced by P. cecum perforation and fecal material are released into the peritoneal cavity, exacerbating the immune response induced by polymicrobial infection. Mice receiving CLP with fluid resuscitation showed a first (early) high cardiac output phase, followed by Before surgery, patients were given ketamine (Imalgen) e1000 100mg / Kg Merial) and xylazine (Rompun 2% The animals were anesthetized intraperitoneally with 20 mg / kg Bayer. The cecum is ligated with suture at the distal third. The distal part was perforated twice with a 21-gauge needle. All mice were rehydrated and kept hydrated for 4 days after surgery. For days, painkillers (Buprenorphine) Axience 0.3 The mice were treated with 10 mg / kg twice daily. 2. LPS Administration Source of 10 mg / ml stored in 0.9% NaCl corrected for mouse weight LPS was administered intraperitoneally to achieve a dose of 10 mg / kg from the intraperitoneal cavity. To confirm the effect of Lipogems® on disease severity (disease score and survival rate) This was carried out for this purpose.

[0022] In both models, control animals received the same dose of ketamine (Imalgene 1000 100mg / Kg Merial) and xylazine (Rompun2% 20mg / All surgical procedures were performed in the morning. All experiments were performed under a sterile hood.

[0023] Collection of Lipogems® Each patient provided unopposed informed consent for the use of surgical tissue for research. (otherwise it will be destroyed). French National Authority for Pe After the National Data Protection Approval Patient data were collected in a prospectively maintained database (Commissi on Nationale Informatique et liberte:CNI L.https: / / www.cnil.fr.Registration numbe r 1922081-02.02.2016).

[0024] -Collection of human adipose tissue Donor sites for adipose tissue harvest using techniques derived from traditional surgical liposuction and The lower abdominal or flank area was selected by endoscopic surgery. Multiple 1×2 mm elliptical holes were placed along it. A blunt 13G cannula was used for adipose tissue collection. A 10cc syringe and This connected, disposable cannula allows for fast, non-invasive delivery in just a few cannula strokes. This allows for selective collection of adipose tissue. Selected areas are then filled with saline and 1:1000 epinephrine. Adipose tissue was harvested 10 min after tumescent infiltration with phosphorus. .

[0025] - Treatment of adipose tissue with the Lipogems® device The harvested adipose tissue was immediately processed in the Lipogems® closed system. The mechanical processes of microfragmentation, washing, and filtration are carried out in a system completely immersed in physiological solution. This allows for a reduction in volume while minimizing any traumatic effects on the cell product. The presence of air is avoided. The resulting product is kept within an intact stromal vascular niche. It contains pericytes / MSCs and can readily interact with recipient tissue after transplantation. Purified Lipogems® adipose tissue was collected into a 60cc syringe and then To remove excess saline, place in a container to gently decant by gravity. Next, transfer the Lipogems® product into several 1 cc syringes and add The mice were then re-injected intraperitoneally into the control mice.

[0026] Cyclooxygenase inhibitors Mice were injected with a cyclooxygenase inhibitor (Lipogems®). Indomethacin (10 mg / kg) was injected intraperitoneally to deliver the target drug. (Sigma-Aldrich, I7378, USA), or SC-560 (a selective inhibitor of COX1 used at 6 mg / kg; Sigma-Aldrich) Aldrich, S2064, USA), or NS-398 (used at 6 mg / Kg) Selective COX2 inhibitors (Sigma-Aldrich, N194, USA) Injections were administered every 8 hours for 24 hours. All injections were weight-adjusted. and starting from a 10 mg / ml solution freshly prepared in 0.9% NaCl prior to injection. The control group was injected with the same volume of 0.9% NaCl. For this set of experiments, n=8 n=8 septic CLP mice, n=8 septic CLP+Lipogems® mice, and n=5 controls (non-septic uninjected mice). I returned it.

[0027] Luminex® (Multiplex Immunoassay) Blood from an intracardiac puncture was collected into a heparin-coated Eppendorf tube and syringe. The blood was spun at 1500 rpm for 10 minutes at 4°C, and the supernatant (plasma) was collected. The frozen plasma was thawed and diluted with Luminex® complex cytokines and and chemokine analysis (Bio-Plex® Pro™ Mouse Cytokine ine Standard 23-Plex, Group I and Standard The study of inflammatory cytokines was performed using the Control mice, septic (CLP) mice, and septic mice injected with Lipogems® For this set of experiments, n=7 septic CLP mice, n=7 Sepsis CLP+ Lipogems® mice and n=5 controls (non-septic controls) Mice without injection were used.

[0028] Hematoxylin and eosin (H&E) staining and immunohistochemistry For H&E analysis, organs were fixed in 4% formaldehyde for 2 days and then frozen in parafoam at 60°C. The tissue was then sectioned at 50 μm and dried overnight. After washing with alcohol and ammonia, the specimen was immersed in eosin for 30 seconds. After each step, the sections were rinsed with distilled water. Dehydrate the sections by treatment with alcohol at different degrees (70%, 80%, 95%, and 100%). Finally, the sections were treated with xylene and covered with glass slips. For immunostaining, frozen serial 10 μm sections were prepared using standard techniques. All tissues were fixed in 4% paraformaldehyde for 15 min and washed with PBS. In PBS with 0.5% TritonX100 and 3% BSA (bovine serum albumin), After extensive washing, primary antibodies were incubated for 1 h in PBS at 37°C. The sections were then washed with PBS and exposed to secondary antibodies for 50 min at room temperature. (Histofine, Simple Stain Max PO Pellet directed to the correct host oxidase polymer). All immunohistochemical stainings were performed simultaneously with negative controls (staining without primary antibody). For histology counts, n=4 control and n=5 septic mice (CL P), or sepsis (CLP) + Lipogems® injection, n=5 Counts were performed manually in a double-blind manner. The antibody list used was as follows: anti-CD3; Dako#A0452;Anti-CD4 Pharmigen#550280;Anti-F4 / 80 Invitrogen♯RM2600;Anti-CD45R(B220)Invitrogen #A14748; anti-biotinylated Jackson #712065150.

[0029] measurement Primary Endpoint The primary endpoint was the assessment of inflammatory scores 24 hours after CLP (Table 1). For comparison and confirmation purposes, this score was compared with that in mice injected with 10 mg / kg intraperitoneal LPS. Even if there was a problem, the calculation was done after 24 hours.

[0030] Secondary endpoints Secondary endpoints measured included survival and body temperature up to 21 days after inflammation, asparagus Acetylcholinesterase (ASAT), alanine aminotransferase (AL AT), alkaline phosphatase (AP), lactate dehydrogenase (LDH) and cre Plasma levels of cytokinin kinase (CK), white blood cell counts, and serum creatinine (CL) levels at 24 hours and 21 hours after CLP Plasma levels of pro- and anti-inflammatory cytokines up to day 1, and liver 6 hours after CLP These included the numbers of F4 / 80+, B220+ and CD3+ cells in the liver and kidney.

[0031] Data analysis The sample size was based on previous experiments and the minimum n value to obtain significant results. We previously observed significant differences with low variability in animal death following injection of bone marrow mesenchymal stem cells. After induction of high-grade CLP, 65% mortality occurred, whereas after injection of bone marrow mesenchymal stem cells, 5%. At α=5% and 90% power, n=7. Adipose-derived mesenchymal Evidence (based on laboratory and literature) that mesenchymal stem cells derived from bone marrow may be more efficient than mesenchymal stem cells derived from bone marrow. Based on the above, the higher cell proliferation rate was observed in adipose mesenchymal stem cells compared to bone marrow-derived mesenchymal stem cells. There is experimental evidence (such as the descent of Cain) so n=8 should be sufficient. Data for each condition were compared, except for body temperature, cytokine levels, and white blood cell counts (expressed as mean ± SD). Data are expressed as median [IQR]. *P<0.05; **P<0.01; *** P < 0.001; ns, statistically not significant compared with respective controls.

[0032] Single-blind (sepsis score, temperature, Luminex) or double-blind (clinical biology, tissue Data analysis was performed using GraphPad Prism software. Use the appropriate test (nonparametric Mann-Whitworth unless specified) ney) and a minimum 95% confidence interval for significance were used for statistical analysis; P values ​​shown are <0.05 (*), <0.01 (**), and <0.001 (** *) Figures show median values ​​± confidence intervals for all animals tested or other experimental As indicated for the study. All animals were included in the analysis.

[0033] Effect of Lipogems® on the inflammatory response in septic mice Primary Endpoint First, we investigated the inflammatory scores 24 hours after intraperitoneal injection of either CLP or LPS. Sticky. Sepsis scores (9[8-12 ]; p = 0.006) was significantly greater than that in saline-injected CLP mice (Figure 17[14-20] 1A) was observed to be significantly lower than that in saline-injected CLP mice. In the inflammatory score, the inflammatory score remained high (about 16) for 5 days and increased to 16 on days 7 and 9 after the induction of sepsis. In the saline-injected septic mice, the blood glucose level dropped sharply between 2 and 4 days after the induction of sepsis. On day 1, the score reached 7 [5-9] (Figure 1B). 21 days after induction of sepsis, Lip The inflammatory score of the sepsis group injected with OGEMS® was 3 [2-5]; The mean mean serum serotonin concentration in the control group was 5 [3-6] lower than that in the untreated control group or the saline-injected sepsis group (p < 0.01). = 0.03; Figure 1B).

[0034] Second, we examined the inflammatory scores 24 hours after inflammation in LPS-treated mice. 24 hours after injection, 10% of inflamed mice injected with Lipogems® had -11], whereas the inflammatory score of the inflammatory mice (injected with LPS only) was 16 [15-2 0] (p = 0.0006, Fig. 1C). The LPS-challenged mice reached the limit within 2 days. (defined as having an inflammatory score of 21) reached median survival (Figure 1C,D ).

[0035] Secondary endpoints The survival rate of mice injected intraperitoneally with Lipogems® was significantly higher than that of mice injected with saline. Statistically significant improvement compared to septic mice (65% vs. 25% survival, inflammatory 60 days after induction of the disease (p=0.03; Fig. 2A). CLP mice had higher body temperatures and increased blood flow compared to saline-injected septic mice. had a smaller drop in body temperature (36.3±0.6°C vs. 34.9±0.98°C, respectively). ℃) 24 hours after the induction of inflammation, P = 0.004, Fig. 2B). The difference in body temperature was On the 19th day after inflammation, body temperature in both groups returned to normal (CLP and L 36.9±0.38°C in CLP injected with ipogems® , 37.2 ± 0.3°C in controls, p = 0.34, Figure 2B ). The survival rate of mice injected with Lipogems® after 48 hours of inflammation was 5.1%. The median survival time for saline-injected LPS mice was only 2[1-3] days. The median survival time was 5 [3-6] days ( median survival time), Fig. 1D) (p=0.009; Fig. 1D). Aspartate aminotransferase (ASAT), alanine aminotransferase Alkaline phosphatase (ALAT), alkaline phosphatase (AP), lactate dehydrogenase (LDH) ) and creatine kinase (CK) plasma levels were significantly higher in CL compared with non-inflammatory controls. The results were statistically higher in P mice 24 hours after inflammation (Figure 3A). When injected with IL-1, CLP mice showed biological parameters similar to those of controls ( (Figure 3A). Twenty-four hours after CLP, an initial drop in leukocyte count was observed. This was not observed when mice were injected with Lipogems® (Fig. 3B, p = 0.0722). At later time points after CLP induction, there was no significant difference in leukocyte counts between any of the test condition groups. No differences in numbers were detected ( Fig. 3C , p > 0.05).

[0036] Effect of Lipogems® on cytokine storm and organ immune infiltration In the plasma of septic CLP mice, all cytokine levels were elevated 24 hours after puncture. The levels of the following proinflammatory cytokines were significantly increased in the treated CLP mice compared to untreated CLP mice (Figure 3, Table I). All were significantly reduced in CLP mice injected with Lipogems®: IL-1a, IL-1b, IL-2, IL-5, IL-6IL-12, IL-17, GM -CSF, IFN-g, MIP-1a, MIP-1b, RANTES, TNF-a (Figure 4 , Table I). Focusing on pro-inflammatory IL-6, compared with untreated CLP septic mice, Decreased levels were observed in septic mice injected with Lipogems® (9139 pg / μl ± 4307, p = 0.0079, Figure 4, Table I). In contrast, the following anti-inflammatory cytokines were increased: We found: IL-4, IL-10, and G-CSF (Figure 4, Table I). Focus on anti-inflammatory IL-4. Compared to untreated CLP mice, the Lipogems®-injected CLP mice A significant increase in plasma levels was observed in P mice (16.91 pg / μl ± 1.6 vs. The mean serum creatinine concentration was 23.96 pg / μl ± 3.6, p = 0.008, Figure 4, Table I). One day later, untreated septic mice and those injected with Lipogems® were No differences were found between the mice and the control.

[0037] [Table 1]

[0038] Six days after induction of sepsis, F in the liver of inflammatory CLP mice was significantly decreased compared to control mice. Increases in 4 / 80+, B220+ and CD3+ cell counts were also observed. After injection of 100 mg / kg of erythrocyte sedimentation medium (100 mg / kg of erythrocyte sedimentation medium), the F4 / 80 (Fig. 5A, p=0.01) was significantly increased compared to untreated CLP mice. .033); B220 (Figure 5B, p=0.024); CD3 (Figure 5C; p=0.035) A significant decrease in the number of erythrocytes was observed after Lipogems® injection. There was an overall reduction in all immune cell types tested: F4 / 80 (Figure 5D, p=0.00 14); B220 (Fig. 5E, p=0.05); CD3 (Fig. 5F, p=0.03). In comparison with inflammatory animals, no detectable Gr1-positive cells were found after inflammation. It was decided that these markers would not be included in our analysis.

[0039] Cyclooxygenase on Lipogems® Effect 24 hours after CLP Effect of inhibitors Understanding whether Lipogems® effects are mediated by the COX pathway To achieve this, the previous protocol was repeated with the coadministration of selected COX inhibitors. Specifically, inflammation was induced by CLP, and Lipogems (registered trademark) was administered 2 hours after induction of sepsis. Lipogems® was injected into the mice and the mice were sacrificed 24 hours after CLP. ) + indomethacin injection or Lipogems® + NS-398 injection After 24 hours (inflammatory score = 16.50 [15-18]; p = 0.001 and and 16.00 [12-19] p=0.001), and the inflammatory scores were higher in untreated septic mice. However, the results showed that the α-terminal region of the liposome was unchanged compared to that of the Lipogens (Fig. 6A). The effect of .ALPHA. was not affected after co-injection with SC-560 (inflammatory suppressor Core: 9[8-12] Lipogems® alone vs. 10[8-15]L Lipogems® + SC-560; p=0.65 (Figure 6A). s®, compared with indomethacin (median survival 26 [22-29] days; p=0.12 ) or NS-398 (median survival 21 [18-24] days; p = 0.09). Lower survival rates were observed when Lipogems® alone was co-injected with or Lipogems® + SC-560 when animals were injected with No abnormalities were detected (median survival 60 [55-67] days; p = 0.04, Figure 6B). Lipogems® + indomethacin (3986 ± 1172 leukocytes / ml; p = 0.02) or NS-398 (4068 ± 551 leukocytes / ml, p = 0.01). Co-injection of either Lipogems® or Lipogems® alone (6307 The white blood cell count dropped 3 days after CLP compared with the control group (±516 white blood cells / ml, Fig. 6C). Ipogems® and SC-560 (6025 ± 597 leukocytes / ml, p = 0 No difference in white blood cell count was observed when Lipog Compared with ems alone, Lipogems® Injection of indomethacin with IL-1, IL-2, and IL-2+ increased the production of pro-inflammatory cytokines. Plasma levels of IL-5, IL-6, IL-17, IFN-g, MIP-1, and TNF-a (FIG. 6D, Table II). For example, IL-6 levels were increased by the Lipogems In inflamed mice injected with target + indomethacin, the value was 14,225 pg / μl ± 1,078. in the plasma of inflamed mice injected with Lipogems®. The mean serum creatinine concentration was 151 pg / μl ± 897 (p = 0.028, Fig. 6D, Table II). With the oxygenase-1 inhibitor SC-560, Lipogems® alone Compared with CLP mice injected with IL-17, only the plasma levels of IL-17 were increased, whereas other inflammatory All stimulatory cytokines were unchanged (Table II). For example, IL-6 was 8548 pg of inflamed mice injected with Lipogems® at a concentration of 100 mg / μl ± 971 mg / μl. There was no difference, 9151 pg / μl ± 897 (p = 0.48, Table II).

[0040] Lipogems® + NS-398 Selective Cyclooxygenase-2 Inhibitor Similar results were obtained when co-injected with Lipogems® after CLP and Compared with the group injected with only CLP, IL-1, IL-2, IL-6, and IL- 17, plasma levels of TNF-α increased (Fig. 6D, Table II). When Lipogems® and NS-398 were co-injected into mice, CLP A plasma concentration of 12464 pg / μl ± 2346 was observed 24 hours after administration of CL P and Lipogems® alone (9151 pg / mL) μl ± 897; p = 0.028, Figure 6F). Lipogems® and India Injection of methacin into inflamed mice reduced IL-4 and IL-10 levels 24 hours after CLP. A decrease in plasma levels of IL-13 and IL-14 was detected (Fig. 6D, Table II). and Lipogems®-injected mice were co-injected with indomethacin, The plasma concentration of L-10 was 2364 pg / μl ± 2100. The concentration observed with Ipogems® alone (8839 pg / μl ± 1442; p = 0.028, Fig. 6D, Table II). did not alter levels of IL-10 (8120 pg / μl ± 952). 2, p=0.48, Fig. 6D, Table II), whereas injection of NS-398 suppressed the anti-inflammatory cytokine Reduced plasma levels of IL-4, IL-10, and IL-13 (20% for IL-10). 52 pg / μl ± 1158, p = 0.03, Figure 6D, Table II).

[0041] [Table 2]

[0042] conclusion The data illustrated above demonstrates the efficacy of microfragmented fat (Lipogems®) in the abdominal cavity. These results show that intravenous administration of sucrose effectively reduces the deleterious effects of sepsis, especially during the acute phase of sepsis. Indeed, data show improved survival and mortality in septic mice treated with microfragmented fat. In addition, the mice's body temperature was close to 37°C, and the pro-inflammatory subunits The levels of cytokines are decreased, whereas the levels of anti-inflammatory cytokines are increased. Further treatment of septic mice, such as intraperitoneal administration of tissue, did not show the same results. Furthermore, the data reported above demonstrate that Lipogems® microfragmented fat We demonstrate that it acts via the prostaglandin pathway. In particular, the enzyme activity of COX-2 It is essential for its anti-inflammatory effect. In fact, indomethacin, a potent prostaglandin compound, Administration of Lipogems® Microfragments in Septic Mice Therefore, Lipogems® microfragmented fat blocks the effect of administration of microfragmented fat. affects prostaglandin synthesis and non-COX targets.

[0043] Long-term effects of injection of microfragmented adipose tissue into septic mice Microfragmented fat from Lipogems extract reduces inflammation during the acute phase of sepsis The long-term effects of sepsis include 1) muscle weakness that can last for up to 5 years, and and 2) cognitive impairment. When mice were injected with induced adipose tissue, microglial cells (the brain's immune cells) were not significantly affected. In particular, Lipogems injections were experimentally demonstrated to be effective in preventing the development of septicemia in mice. Deramification of microglial cells in the cortex and hippocampus Thus, Lipogems injections in the chronic phase of sepsis reduced the expression of microglial cells. Improve behavior. In conclusion, injection of microfragmented fat reduces the risk of sepsis-related or sepsis-induced The study has shown that it can prevent or improve / reduce cognitive impairment caused by In addition, the number of Pax7+ cells was measured and the number of Pax7+ cells was increased in septic mice after late administration of Lipogems. They found a reduction in satellite cells in the tumor.

Claims

1. For use in the treatment of a systemic disease / condition or in treating a health condition associated with a systemic disease / condition. US20130233633A1 - Microfragmented fat or compositions containing microfragmented fat for ameliorating harmful health effects - Google Patents The systemic disease / condition is preferably associated with or caused by sepsis. The present invention relates to a method for producing microfragmented fat, or a composition comprising microfragmented fat, comprising the steps of:

2. The disease / condition is a systemic disease / condition, an inflammatory disease / condition, an immune disease / condition, or a chronic and wherein the disease / condition is caused by a sepsis disease / condition.

1. A method for producing a microfragmented fat or a composition comprising microfragmented fat for use according to claim 1. Composition.

3. The disease / condition is related to prostaglandin synthesis and / or non-COX targets. A composition comprising microfragmented fat or microfragmented fat for use according to claim 1 or 2. Composition.

4. Sepsis is in the acute or late stage, and the adverse health effects of the acute stage include changes in body temperature, and procalcitonin elevation, , acute lung injury, shock, renal failure, muscle weakness, cognitive impairment, preferably insomnia, nightmares , vivid hallucinations and panic attacks, extreme fatigue, poor concentration, decreased mental function, low self-esteem, Any one of claims 1 to 3 selected from the group consisting of loss of confidence and anxiety, and multiple organ dysfunction syndrome. Item 14. Microfragmented fat or a composition comprising microfragmented fat for the use described in item 14.

5. The microfragmented fat is a non-enzymatic microfragmented fat, preferably microfragmented using mild mechanical force. and in the presence of a solution, preferably saline, the adipose tissue sample is separated into small classes. Use according to any one of claims 1 to 4, obtained by progressively reducing 2. A composition comprising microfragmented fat for use in treating a chronic condition.

6. The microfragmented fat has a diameter of 50 to 5000 μm, preferably 100 to 3000 μm, more preferably Preferably, the thickness is 200 to 2500 μm, more preferably, the thickness is 300 to 1500 μm, and even more preferably The composition according to any one of claims 1 to 5, further comprising fat clusters having a size in the range of 400 to 900 μm.

2. Microfragmented fat or a composition comprising microfragmented fat for the use according to any one of claims 1 to 11.

7. The microfragmented fat is enriched in mesenchymal stem cells (MSCs) and / or pericytes and / or contains adipose clusters containing adipose stem cells, said cells preferably being in their native / intact form. The microfragment for use according to any one of claims 1 to 6, which maintains the stromal vascular niche.

2. A composition comprising microfragmented fat or microfragmented fat.

8. The microfragmented fat is derived from human adipose tissue, more preferably from the lower abdominal region and / or deriving from human adipose tissue, more preferably isolated / aspirated tissue, from the flank region.

8. Microfragmented fat or comprising microfragmented fat for use according to any one of claims 1 to 7 composition.

9. The septic condition / disease involves misregulation of pro-inflammatory molecules, the molecules being preferably L-1a, IL-1b, IL-2, IL-5, IL-6, IL-12, IL-17, GM -CSF, IFN-g, MIP-1a, MIP-1b, RANTES, procalcitonin The molecule according to any one of claims 1 to 8, selected from creatine kinase and TNF-a.

2. Microfragmented fat or a composition comprising microfragmented fat for the use according to claim 1.

10. The microfragmented fat may be intraperitoneally, intramuscularly, alveolarly, intranasally, intrapulmonary, intrathecally, intralaminarly, intracranially ... via the nasal plate (preferably using the nasal route) or for lymphatic administration. The microfragmented fat or microfragmented fat for use according to any one of claims 1 to 8. A composition comprising fat.

Citation Information

Patent Citations

  • Apparatus and method for preparing tissue for transplantation, particularly adipose tissue, from lobular fat extracted by liposuction.

    JP2013526868A

  • Fat and its medical uses

    JP7657015B2